下载文档原格式
抗骨增生胶囊治疗骨质疏松症的疗效观察作者单位：262200 山东省诸城市人民医院骨质疏松症是指单位体积内骨质量减少，以致骨结构改变，从而导致骨脆性增加甚至骨折，周身骨痛，是一种慢性骨病。
骨质疏松症多发于老年人和绝经后的妇女。
据有关部门统计，该病的发病率已超过25%[1]，是目前危害老年人健康的一大疾病；它不仅降低了老年人的生活质量，还耗费了大量的医药费用。
目前，治疗骨质疏松症的药物按照其作用可分为3类：①抗骨重吸收药物，包括雌激素、降钙素和双磷酸盐。
②促骨形成药物，以氟化物为主。
③骨钙化药物，主要有钙剂、维生素d及其衍生物。
寻找安全有效、价格适中的骨质疏松症的治疗药物和最佳用药量，是当前研究的热点。
我们应用抗骨增生胶囊对30例绝经后骨质疏松症患者进行了为期6个月的治疗观察，现将资料与结果报告如下。
1 资料与方法1.1 一般资料 30例绝经后骨质疏松妇女，年龄43～69岁，平均63岁，自然停经1年以上，体格检查各重要脏器无器质性病变，接受治疗前6个月未曾服用影响骨代谢的药物。
1.2 治疗方法口服抗骨增生胶囊（江苏省连云港康缘制药有限责任公司生产，0.35 g/粒），3次/d，3粒/次，连续服用6个月。
1.3 骨密度（bmd）测定采用dcx检查测定尺桡骨bmd。
1.4 血生化指标检查方法治疗前后清晨抽取静脉血5 ml，检验生化指标，ca、p、bun。
2 结果2.1 bmd 30例患者经抗骨增生胶囊治疗6个月后，治疗前与治疗后的bmd平均值分别为（0.715±0.039）、（0.741±0.040）g/cm2，增加了3.18%，治疗前后比较有明显统计学差异（t=10.3151，p0.01）；p（mmol/l）治疗前后分别为：（1.17±0.16）、（1.22±0.17），（t=0.68，p>0.01）；bun（mmol/l）治疗前后分别为：（4.90±2.10）、（4.81±2.11），（t=0.32，p>0.01）。
抗骨增生胶囊含药血清对大鼠成骨细胞增殖、分化的影响宋永周;刘会玲;马维;童九辉;李飞;孙淑芹【摘要】目的探讨抗骨增生胶囊含药血清对大鼠成骨细胞增殖、分化及骨保护蛋白(OPG)和核因子-κB受体活化子配体(RANKL)蛋白表达的影响.方法采用中药血清药理学方法制备含抗骨增生胶囊大鼠血清.取乳鼠颅骨,利用复合胶原蛋白酶反复消化,离心,体外培养成骨细胞.加入不同浓度的抗骨增生胶囊含药血清进行干预,噻唑蓝(MTT)法检测中药血清对成骨细胞增殖的影响,测定碱性磷酸酶(ALP)活性,Western Blot检测OPG和RANKL蛋白表达.结果成骨细胞经抗骨增生胶囊含药血清作用后,细胞的生长呈现不同程度的增殖,中、高剂量中药组在24、48、72 h均有明显的促进作用(P＜0.01),且呈剂量依赖性.低剂量中药组在24、48 h时与空白对照组比较差异无统计学意义(P＞0.05),72 h时作用较强(P＜0.05).除低剂量组培养24 h外,低、中、高剂量中药组培养24、48、72 h后,ALP分泌均呈不同程度增加,均有明显的促进作用(P＜0.01).成骨细胞经过抗骨增生胶囊含药血清低、中、高剂量作用72 h后,对比值进行统计分析,与空白对照组比较,OPG表达明显升高(P＜0.01),RANKL表达明显降低(P＜0.01).结论抗骨增生胶囊含药血清可以促进成骨细胞的增值、分化,从而促进骨形成.【期刊名称】《河北中医》【年(卷),期】2016(038)008【总页数】5页(P1187-1190,1194)【关键词】成骨细胞;碱性磷酸酶;细胞增殖;药物作用;中药疗法【作者】宋永周;刘会玲;马维;童九辉;李飞;孙淑芹【作者单位】河北医科大学第二医院骨科,河北石家庄050000;河北医科大学第二医院骨科,河北石家庄050000;河北医科大学第二医院骨科,河北石家庄050000;河北医科大学第二医院骨科,河北石家庄050000;河北省定州市人民医院CT核磁科,河北定州073000;河北省定州市人民医院CT核磁科,河北定州073000【正文语种】中文【中图分类】R-332;RR285.5;R329.24;R329.28;R681.053.1骨质疏松症是以骨量减少，骨的微观结构退化为特征，致使骨的脆性增加，易于发生骨折的一种全身性骨骼疾病[1-2]。
基础医学中国组织工程研究与临床康复 第 12 卷 第 24 期 2008–06–10 出版Journal of Clinical Rehabilitative Tissue Engineering Research June 10, 2008 Vol.12, No.24抗骨增生胶囊含药血清对软骨细胞增殖凋亡及基质金属蛋白酶分泌的影响*☆宋永周1，刘会玲1，崔慧先2，郭 威2，李 莎2Seropharmacological effects of Kanggu Zengsheng capsules on the proliferation, apoptosis and matrix metalloproteinase secretion of chondrocytes in vitroSong Yong-zhou1, Liu Hui-ling1, Cui Hui-xian2, Guo Wei2, Li Sha2 Abstract1Department of Orthopaedics, Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China; 2 Department of Anatomy, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China Song Yong-zhou ☆ , Studying for doctorate, Attending physician, Department of Orthopaedics, Second Hospital of Hebei Medical University, Shijiazhuang 050000, Hebei Province, China yongzhousong@ Correspondence to: Cui Hui-xian, Tutor of doctor, Professor, Department of Anatomy, Hebei Medical University, Shijiazhuang 050017, Hebei Province, China cuihxf@yahoo. Supported by: the Science and Technology Research and Development Program of Hebei Province, No. 052761617* Received: 2008-02-03 Accepted: 2008-05-28BACKGROUND: Kanggu Zengsheng capsules exhibit efficacy in treating joint disease. There are many basic studies focusing on cervical syndrome or other joint diseases. OBJECTIVE: To observe the seropharmacological effects of Kanggu Zengsheng capsules on the proliferation, apoptosis and secretion of matrix metalloproteinase 13 (MMP-13) of chondrocytes induced byinterleukin-1β (IL-1β). DESIGN, TIME AND SETTING: The in vitro cytology trial was performed at the Cell Laboratory of Department of Anatomy of Hebei Medical University from March to September 2007. MATERIALS: One 1-week-old SD rat was prepared for chondrocyte culture; the serum of ten SD rats weighing 200 g was obtained after intragastric administration with medicine water solution. METHODS：Articular chondrocytes were obtained from the cartilage of 1-week SD rat using digestion method by collagenase NB4, followed by primary culture and subculture of chondrocytes. It was divided into 3 groups: control group, 90%L-DMEM＋10% serum, and normal saline; IL-1β group, 90% DMEM＋10% serum+5 μg/L IL-1β; and Kanggu Zengsheng capsule-conditioned serum +IL-1β group, 90%DMEM＋10% medicine-conditioned serum+5 μg/L IL-1β). After 72 hours incubation, the chondrocytes were digested into single cell suspension. Then they were incubated in the 96-well culture plate with the density of 1×108 L 1 , 100 μL per well and six wells for per group. MAIN OUTCOME MEASURES: The seropharmacological effects of Kanggu Zengsheng capsules on the proliferation of chondrocytes were observed by inverted microscope. The absorbance was measured by methyl thiazolyl tetrazolium method (MTT). The apoptosis ratio was analyzed by flow cytometry. The concentration of MMP-13 on the supernatants was measured by Elisa kit. RESULTS: In normal condition, the chondrocytes aligned closely with uniform shape, and few died cells were seen. In control group, the proliferation was slow, and the chondrocytes were dispersed. In IL-1βgroup, the cells aligned scarcely, and vacuolus and irregular nucleus could be seen in some of chondrocytes. In Kanggu Zengsheng capsules serum+IL-1βgroup, the cellular proliferation was quicker than those in IL-1βgroup, cell body was significantly enlarged and nucleus was uniform. The quantity of chondrocytes in IL-1βgroup decreased obviously, while the apoptosis ratio increased significantly. The MMP13 concentration of its supernatants also increased obviously. Kanggu Zengsheng capsules could inhibit the effects induced by IL-1β. CONCLUSION: Kanggu Zengsheng capsule-conditioned serum can inhibit chondrocyte apoptosis induced by IL-1βand reduce secretion of MMP-13 in vitro. Song YZ, Liu HL, Cui HX, Guo W, Li S. Seropharmacological effects of Kanggu Zengsheng capsules on the proliferation, apoptosis and matrix metalloproteinase 13 secretion of chondrocytes in vitro.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(24):4642-4646 [/zglckf/ejournal/upfiles/08-24/24k-4642(ps).pdf]摘要背景：抗骨增生胶囊在治疗骨关节疾病方面有很好的疗效，基础研究多集中于颈椎病等骨关节疾病上。
抗骨质增生胶囊联合玻璃酸钠关节腔内注射治疗膝骨性关节炎的疗效观察李正球（韶山市人民医院，湖南 韶山 411300）摘要:目的 探讨分析抗骨质增生胶囊联合玻璃酸钠关节腔内注射治疗膝骨性关节炎的临床效果。
方法 随机选取2010年6月至2011年5月在我院住院治疗的膝骨性关节炎患者64例78个膝关节，将他们随机平均分成试验组和对照组，对照组每次在患者的膝关节膝眼处或髌上囊腔内注射玻璃酸钠，并口服盐酸氨基葡萄糖，而试验组患者，在对照组的基础上再口服抗骨质增生胶囊，5周后对比两组患者的治疗情况。
结果 5周后，经过抗骨质增生胶囊联合玻璃酸钠治疗的试验组中的39个膝关节有32个的疼痛得到了很好的缓解，有效率达到了82.05%，而对照组中仅有24个得到了缓解，有效率仅为61.54%，明显低于试验组，差异有统计学意义（P<0.05）。
结论 抗骨质增生胶囊联合关节腔内注射玻璃酸钠治疗能够很好地缓解膝骨性关节炎患者的疼痛症状，值得在临床上进一步推广应用。
关键词:抗骨质增生胶囊；玻璃酸钠；膝骨性关节炎；临床效果中图分类号:R 684.3 文献标识码:B骨性关节炎作为临床骨科的一种常见病，在老年人群里有很高的发病率，故又称为老年性膝关节炎，主要的临床症状有膝关节肿胀、疼痛、畸形、活动受限，肌肉萎缩、关节功能障碍，有极高的致残率。
在临床上对这种病的治疗药物主要是肾上腺皮质激素类药物和非甾体消炎药，但是这两种药并不能达到理想的治疗效果，并且容易引发不良反应[1]。
为了探讨分析抗骨质增生胶囊联合玻璃酸钠关节腔内注射治疗膝骨性关节炎的临床效果，本文随机选取了2010年6月至2011年5月在我院住院治疗的64例膝骨性关节炎患者，并对其中的一部分采用了抗骨质增生胶囊联合关节腔内注射玻璃酸钠的方法治疗，取得了很好的效果，现将结果报道如下:1 资料与方法1.1一般资料随机选取2010年6月至2011年5月在我院住院治疗的膝骨性关节炎患者64例78个膝关节，其中双膝16例，右膝25例，左膝21例，病程为0.5-19年，所有患者均符合美国风湿病学院制定的膝关节股性关节炎的诊断标准。
